Market research
VIR Vir Biotechnology Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- 1.59
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US92764N1028
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- 1.59
About
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VIR discussion.
5 years, 4 months ago
Vir Biotechnology, Inc is currently in a long term downtrend where the price is trading 5.2% below its 200 day moving average.
From a valuation standpoint, the stock is 94.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 75.8.
Vir Biotechnology, Inc's total revenue sank by 92.2% to $76K since the same quarter in the previous year.
Its net income has increased by 100.0% to $-299 since the same quarter in the previous year.
Finally, its free cash flow fell by 108.9% to $-84M since the same quarter in the previous year.
Based on the above factors, Vir Biotechnology, Inc gets an overall score of 2/5.